Preetam Shah

Filings by Preetam Shah span 3 companies, the busiest being Cidara Therapeutics, Inc., Brainstorm Cell Therapeutics Inc. and Elicio Therapeutics, Inc. We count 14 filings; the first trade dates from 6 September 2019 and the latest from 2 February 2026.

Market trades split into 2 purchases (€68k) and 3 sales (€33k). Purchases outweigh sales by €35k. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Besides market trades, the filings include 8 share grants and 1 option exercise.

On 3 February 2026 came the latest disclosure, a share grant in Elicio Therapeutics, Inc. The last purchase on record was published on 15 November 2021, which is 1,804 days ago. Filings reach the SEC (Form 4) feed a median of 3 days after the trade. For comparison, the SEC allows two business days to file a Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.